Company Analysis Akoya Biosciences, Inc.
1. Summary
Advantages
- Price (3.03 $) is less than fair price (4.86 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
- The stock's return over the last year (-39.8%) is lower than the sector average (-37.33%).
- Current debt level 43.63% has increased over 5 years from 27.45%.
- The company's current efficiency (ROE=-117.77%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Akoya Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 8.9% | -1.7% | 0.8% |
| 90 days | 5.9% | -40.1% | 6.4% |
| 1 year | -39.8% | -37.3% | 27.4% |
AKYA vs Sector: Akoya Biosciences, Inc. has slightly underperformed the "Healthcare" sector by -2.48% over the past year.
AKYA vs Market: Akoya Biosciences, Inc. has significantly underperformed the market by -67.25% over the past year.
Stable price: AKYA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AKYA with weekly volatility of -0.7655% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3.03 $) is lower than the fair price (4.86 $).
Price significantly below the fair price: The current price (3.03 $) is 60.4% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.19) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (4.19) is higher than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.33) is lower than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (2.33) is lower than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.83) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.83) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 55.81% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (55.81%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-117.77%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-117.77%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-35.11%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-35.11%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 11.06.2024 | McKelligon Brian President and CEO |
Sale | 2.08 | 15 600 | 7 500 |
| 11.06.2024 | McKelligon Brian President and CEO |
Purchase | 0.3 | 2 250 | 7 500 |
| 07.09.2023 | Pla Frederic Chief Operating Officer |
Purchase | 4.6 | 92 000 | 20 000 |
| 22.12.2022 | DRISCOLL JOSEPH Chief Financial Officer |
Purchase | 0.44 | 110 000 | 250 000 |
| 02.12.2022 | Nolan Garry Ph.D. Director |
Sale | 13.25 | 14 575 | 1 100 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
